CN112870309A - Application of traditional Chinese medicine composition in preparation of medicine for treating or improving gastrointestinal diseases - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating or improving gastrointestinal diseases Download PDFInfo
- Publication number
- CN112870309A CN112870309A CN202110412331.6A CN202110412331A CN112870309A CN 112870309 A CN112870309 A CN 112870309A CN 202110412331 A CN202110412331 A CN 202110412331A CN 112870309 A CN112870309 A CN 112870309A
- Authority
- CN
- China
- Prior art keywords
- parts
- fried
- traditional chinese
- scorched
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of Chinese patent medicines, and relates to application of a Chinese medicinal composition in preparing a medicament for treating or improving gastrointestinal diseases. Wherein the raw materials of the traditional Chinese medicine composition comprise charred medicated leaven, charred hawthorn, charred malt, white paeony root, codonopsis pilosula, poria cocos, fried bighead atractylodes rhizome, costustoot, fructus amomi, vinegar rhizoma corydalis and honey-fried licorice root. The invention discovers that the traditional Chinese medicine composition has excellent performance on treating gastric mucosa injury and improving the gastric mucosa injury, and provides possibility for developing drugs related to the gastric mucosa.
Description
Technical Field
The invention belongs to the technical field of Chinese patent medicines, and relates to a new medical application of a compound traditional Chinese medicine composition.
Background
After a certain degree of traumatic stimulation, the gastric mucosa can initiate a rapid repair mechanism to rapidly restore the integrity of the gastric mucosa, so as to avoid the development of damage to the deep layer, which is an important barrier capability of the gastric mucosa against diseases.
The mechanism of rapid repair of gastric mucosa, which is mainly represented by the migration of living cells around or deep in the damaged area, is a rapid response because it does not require DNA replication and protein synthesis, and only requires appropriate modification of a series of functional proteins in the cell, but is still unclear.
Compound Chinese medicinal Massa Medicata Fermentata digestion promoting oral liquid (SQXSOS) comprises Massa Medicata Fermentata, fructus crataegi preparata, fructus Hordei Germinatus preparata, radix Paeoniae alba, radix Codonopsis, Poria, bran-parched Atractylodis rhizoma, radix aucklandiae, fructus Amomi, vinegar-processed rhizoma corydalis, and radix Glycyrrhizae Preparata, and has effects of promoting digestion, invigorating stomach, invigorating spleen and regulating qi-flowing. The traditional Chinese medicine is currently used for treating spleen and stomach weakness of children caused by improper feeding or improper diet.
Disclosure of Invention
The invention provides a new application of a traditional Chinese medicine composition in the aspect of medicine on the basis of the prior art.
The object of the invention can be achieved by the following measures:
the application of a traditional Chinese medicine composition in preparing a medicine for treating or improving gastrointestinal diseases is characterized in that raw material medicines of the traditional Chinese medicine composition comprise scorched medicated leaven, scorched hawthorn fruit, scorched malt, white paeony root, dangshen, tuckahoe, stir-fried largehead atractylodes rhizome, costustoot, villous amomum fruit, vinegar-processed corydalis tuber and honey-fried licorice root.
The gastrointestinal diseases in the present invention include, but are not limited to, gastric mucosal injury, diseases associated with gastric mucosal injury, gastric ulcer, duodenal ulcer, gastritis, and the like.
The composition can be used for preparing medicine for treating gastrointestinal diseases including gastric mucosa injury, diseases related to gastric mucosa injury, gastric ulcer, duodenal ulcer, and gastritis.
The invention relates to gastric mucosal lesions, in particular to mucosal lesions including the antrum of the stomach.
Further, the present invention is directed to treating or ameliorating gastric mucosal injury including reducing inflammatory cell hyperacidity and ameliorating cell alignment disorders.
The traditional Chinese medicine composition can be prepared into oral preparations with pharmaceutically acceptable auxiliary materials, including but not limited to pills, powder, paste, granules, syrup, oral liquid or capsules.
The traditional Chinese medicine composition comprises the following raw material medicines: 10-20 parts of scorched medicated leaven, 10-20 parts of scorched hawthorn fruit, 10-20 parts of scorched malt, 20-30 parts of white peony root, 10-20 parts of pilose asiabell root, 10-20 parts of tuckahoe, 7-10 parts of fried bighead atractylodes rhizome, 6-10 parts of costustoot, 4-8 parts of amomum fruit, 10-15 parts of vinegar rhizoma corydalis and 5-15 parts of honey-fried licorice root.
In a preferred scheme, the composition of each raw material medicament in the traditional Chinese medicine composition comprises: 13-17 parts of scorched medicated leaven, 13-17 parts of scorched hawthorn fruit, 13-17 parts of scorched malt, 23-27 parts of white peony root, 13-17 parts of pilose asiabell root, 13-17 parts of tuckahoe, 7-9 parts of fried largehead atractylodes rhizome, 7-9 parts of costustoot, 4-7 parts of villous amomum fruit, 11-14 parts of vinegar rhizoma corydalis and 8-12 parts of honey-fried licorice root.
In a more preferred scheme, the raw material medicaments of the traditional Chinese medicine composition comprise: 15 parts of stir-fried hawthorn, 15 parts of stir-fried medicated leaven, 15 parts of stir-fried malt, 25 parts of white paeony root, 15 parts of codonopsis pilosula, 15 parts of poria cocos, 8.5 parts of stir-fried bighead atractylodes rhizome, 8 parts of costustoot, 6 parts of fructus amomi, 12 parts of vinegar-processed rhizoma corydalis and 10 parts of honey-fried licorice root.
The traditional Chinese medicine composition is prepared into pills, powder, paste, granules, syrup, oral liquid or capsules with pharmaceutically acceptable auxiliary materials. The preparation method of the oral liquid comprises the following steps:
step 1, adding 8-40 times of water into fructus amomi, elecampane and fried bighead atractylodes rhizome, extracting and collecting volatile oil;
step 2, decocting the residue liquid medicine after collecting the volatile oil and other medicinal materials with water for 2-3 times, adding 6-10 times of water each time, decocting for 1-3 hours, combining the decoctions, filtering and concentrating;
step 3, adding ethanol to make the alcohol content reach 55-75%, refrigerating for 10-48 hours, precipitating, filtering, recovering ethanol from the filtrate under reduced pressure until no alcohol smell exists,
and 4, adding the volatile oil, the surfactant, the taurine, the aspartame or the sucralose and the preservative, adjusting by using distilled water, refrigerating, filtering, filling the filtrate, and sterilizing to obtain the oral liquid.
In one scheme, the traditional Chinese medicine composition is prepared into oral liquid with pharmaceutically acceptable auxiliary materials, and the oral liquid is medicated leaven digestion-promoting oral liquid.
The invention discovers that the traditional Chinese medicine composition has excellent performance on treating gastric mucosa injury and improving the gastric mucosa injury, and provides possibility for developing drugs related to the gastric mucosa.
Drawings
FIG. 1: SQXSOS improved gastric mucosal damage in model rats;
FIG. 2: SQXSOS significantly reversed the abnormally high transcription of AKT1, TP53, MAPK1, STAT3 in the gastric antrum tissue of model rats;
FIG. 3: the SQXSOS remarkably reduces the abnormally high expression of AKT1, TP53 and MAPK1 in the gastric antrum tissue of a model rat and reduces the expression level of STAT 3;
FIG. 4: SQXSOS significantly reversed abnormally elevated serum oxyntomodulin levels in model rats;
FIG. 5: SQXSOS significantly reversed abnormally reduced serum ghrelin levels in model rats.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood in the art to which this invention belongs. In order to make the technical problems solved by the present invention clear, the present invention is further described below with reference to specific examples.
Medicated leaven oral liquid (SQXSOS, lot 191219) was purchased from Yangzhou pharmaceutical group, GmbH Biotechnology, Inc. was purchased from SPF male SD rats 17-21 days old, Cinax Armoraceae (lot 191107419) was produced from Sian Yang Seng pharmaceutical group, Inc. (Sichuan), stomach invigorating and digestion promoting oral liquid (JWxsos, lot 1911022) was purchased from Jichuan pharmaceutical group, Inc.
Preparation of animal model (modeling): 16 male SD rats (with the weight of 40-70 g) with the age of 17-21 days are selected, 8 male SD rats are used as blank control groups, 8 male SD rats are used as model building groups, and high-fat feed (formula: 5% of dried fish floss, 5% of fresh eggs, 10% of milk powder, 15% of soybean meal, 10% of white sugar and 55% of fat pork) is continuously fed for 30 days (model building). Feeding the rats with normal drinking water while keeping the rats at proper temperature and humidity.
Example 1:
in the present example, 8 young SD rats were used as experimental animals, and each group was divided into a blank group, a model group, a positive drug morpholine group (morpholine 3.78mg/kg), a positive drug JWXSOS group (stomach invigorating and digestion promoting oral liquid 2.52mL/kg), an SQXSOS low dose group (medicated leaven digestion promoting oral liquid 3.78mL/kg) and an SQXSOS high dose group (medicated leaven digestion promoting oral liquid 7.56 mL/kg).
The rats except the blank group are molded and fed for 30 days by the method for preparing the animal model, and the rats in each group are changed to be fed with normal feed in 31-44 days to return to the natural diet state. In 31 days to 44 days of the experiment, 3.78mg/kg of positive drug morpholine group rats, 2.52mL/kg of positive drug JWXSOS group rats, 3.78mL/kg of SQXSOS low-dose group rats, 7.56mL/kg of SQXSOS high-dose group rats and equal amount of physiological saline are respectively administered once a day.
After the administration, rat antrum tissue was collected, embedded in paraffin, and sectioned (5 μm) and HE stained. The conditions of gastric mucosa injury, inflammatory cell infiltration and the like are observed by the stained section under the condition of 200 times of magnification of a microscope, and experimental results show that the medicated leaven digestion oral liquid can obviously relieve the mucosal injury of the gastric antrum part of a model rat, reduce the extreme moistness of inflammatory cells, and improve the pathological characteristics of cell arrangement disorder and the like (figure 1).
Example 2:
young SD rats are used as experimental animals, each group comprises 8 animals, and the animals are divided into a blank group, a model group, a positive drug morpholine group (morpholine 3.78mg/kg), a positive drug JWXSOS group (stomach invigorating and digestion promoting oral liquid 2.52mL/kg), an SQXSOS low dose group (medicated leaven digestion promoting oral liquid 3.78mL/kg) and an SQXSOS high dose group (medicated leaven digestion promoting oral liquid 7.56 mL/kg).
Except for the blank group, the rats in other groups are subjected to model feeding for 30 days by the method for preparing the animal model, and the rats in each group are fed with normal feed in 31-44 days to return to the natural diet state. And in 31 days to 44 days of the experiment, 3.78mg/kg of positive drug molsidine group rats, 2.52mL/kg of positive drug JWXSOS group rats, 3.78mL/kg of SQXSOS low dose group rats, 7.56mL/kg of SQXSOS high dose group rats and the same amount of physiological saline are respectively administered once a day.
After the experiment is finished, the gastric antrum tissues of the rats in each group are cut into pieces, and the transcription and expression levels of AKT1, TP53, MAPK1 and STAT3 in the gastric antrum tissues of the rats in each group are measured by a PCR method and a western blot method. The transcriptional level was determined to be significantly higher in rats from the model rats than in rats from the blank group for AKT1, TP53, MAPK1 and STAT3 in antrum tissue, whereas SQXSOS administration significantly reversed the abnormally elevated transcriptional level of the above criteria in antrum tissue of model rats (FIG. 2).
The expression level of AKT1, TP53 and MAPK1 in the gastric antrum tissues of model rats is obviously higher than that of a blank control group (but the STAT3 expression level is not obviously different from that of the blank control group) by measuring the expression level of each gene corresponding to the protein in the gastric antrum tissues of the rats by a western blot method. After the SQXSOS is administrated, the expression levels of AKT1, TP53, MAPK1 and STAT3 in the gastric antrum tissues of rats of each model are obviously reduced, wherein the expression levels of AKT1, TP53 and MAPK1 approach to normal levels (namely blank control group data) after the SQXSOS is administrated (figure 3), and the medicated leaven digestion oral liquid has a treatment effect on gastric mucosal injury.
Example 3:
young SD rats are used as experimental animals, each group comprises 8 animals, and the animals are divided into a blank group, a model group, a positive drug morpholine group (morpholine 3.78mg/kg), a positive drug JWXSOS group (stomach invigorating and digestion promoting oral liquid 2.52mL/kg), an SQXSOS low dose group (medicated leaven digestion promoting oral liquid 3.78mL/kg) and an SQXSOS high dose group (medicated leaven digestion promoting oral liquid 7.56 mL/kg).
Except for the blank group, the rats in other groups are subjected to model feeding for 30 days by the method for preparing the animal model, and the rats in each group are fed with normal feed in 31-44 days to return to the natural diet state. And in 31 days to 44 days of the experiment, 3.78mg/kg of positive drug molsidine group rats, 2.52mL/kg of positive drug JWXSOS group rats, 3.78mL/kg of SQXSOS low dose group rats, 7.56mL/kg of SQXSOS high dose group rats and the same amount of physiological saline are respectively administered once a day.
After the experiment, 1.5mL of blood was collected from the retroorbital vein of each rat, and after standing for 30min, the rat was rapidly centrifuged at 3000rpm at 4 ℃ for 20min to obtain an upper serum sample. The ELISA kit is used for measuring the levels of Motilin (MTL), Gastrin (GAS), somatostatin (SS), acetylcholine (Ach), Substance P (SP), Dopamine (DA), Vasoactive Intestinal Peptide (VIP), Corticotropin Releasing Hormone (CRH), 5-hydroxytryptamine (5-HT) and Calcitonin Gene Related Peptide (CGRP) in the plasma of each group of rats, and after the administration is finished, the serum levels of SS, VIP, DA, CGRP and CRHC which are abnormally increased in a model rat can be remarkably reduced by the medicated leaven digestion oral liquid administration (figure 4), and meanwhile, the levels of GAS, Ach, MTL, 5-HT and SP which are abnormally reduced in a serum model rat are remarkably increased (figure 5). This example demonstrates that administration of SQXSOS results in abnormally altered levels of oxyntomodulin in model rats that are normalized and have therapeutic effects on gastric mucosal damage.
Claims (10)
1. The application of a traditional Chinese medicine composition in preparing a medicine for treating or improving gastrointestinal diseases is characterized in that raw material medicines of the traditional Chinese medicine composition comprise scorched medicated leaven, scorched hawthorn fruit, scorched malt, white paeony root, dangshen, tuckahoe, stir-fried largehead atractylodes rhizome, costustoot, villous amomum fruit, vinegar-processed corydalis tuber and honey-fried licorice root.
2. The use of claim 1, wherein the gastrointestinal disorder comprises gastric mucosal damage, a disorder associated with gastric mucosal damage, a gastric ulcer, a duodenal ulcer, or gastritis.
3. The use according to claim 2, wherein the gastric mucosal lesion is a mucosal lesion at the antrum of the stomach.
4. The use according to claim 2, wherein the treatment or amelioration of gastric mucosal damage is a reduction in inflammatory cell lubrication and amelioration of cell alignment disorders.
5. The use of claim 1, wherein the Chinese medicinal composition is formulated with pharmaceutically acceptable excipients into an oral formulation.
6. The use according to claim 5, wherein the oral formulation is selected from the group consisting of pills, powders, dusts, pastes, granules, syrups, oral liquids and capsules.
7. The use of claim 1, wherein the composition of the raw materials of the Chinese medicinal composition comprises: 10-20 parts of scorched medicated leaven, 10-20 parts of scorched hawthorn fruit, 10-20 parts of scorched malt, 20-30 parts of white peony root, 10-20 parts of pilose asiabell root, 10-20 parts of tuckahoe, 7-10 parts of fried bighead atractylodes rhizome, 6-10 parts of costustoot, 4-8 parts of amomum fruit, 10-15 parts of vinegar rhizoma corydalis and 5-15 parts of honey-fried licorice root.
8. The use of claim 7, wherein the composition of the raw materials of the Chinese medicinal composition comprises: 15 parts of stir-fried hawthorn, 15 parts of stir-fried medicated leaven, 15 parts of stir-fried malt, 25 parts of white paeony root, 15 parts of codonopsis pilosula, 15 parts of poria cocos, 8.5 parts of stir-fried bighead atractylodes rhizome, 8 parts of costustoot, 6 parts of fructus amomi, 12 parts of vinegar-processed rhizoma corydalis and 10 parts of honey-fried licorice root.
9. The use according to claim 6, wherein the oral liquid is prepared by the following steps:
step 1, adding 8-40 times of water into fructus amomi, elecampane and fried bighead atractylodes rhizome, extracting and collecting volatile oil;
step 2, decocting the residue liquid medicine after collecting the volatile oil and other medicinal materials with water for 2-3 times, adding 6-10 times of water each time, decocting for 1-3 hours, combining the decoctions, filtering and concentrating;
step 3, adding ethanol to make the alcohol content reach 55-75%, refrigerating for 10-48 hours, precipitating, filtering, recovering ethanol from the filtrate under reduced pressure until no alcohol smell exists,
and 4, adding the volatile oil, the surfactant, the taurine, the aspartame or the sucralose and the preservative, adjusting by using distilled water, refrigerating, filtering, filling the filtrate, and sterilizing to obtain the oral liquid.
10. The use of claim 1, wherein the Chinese medicinal composition is formulated with pharmaceutically acceptable adjuvants into oral liquid, which is Massa Medicata Fermentata digestion promoting oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110412331.6A CN112870309A (en) | 2021-04-16 | 2021-04-16 | Application of traditional Chinese medicine composition in preparation of medicine for treating or improving gastrointestinal diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110412331.6A CN112870309A (en) | 2021-04-16 | 2021-04-16 | Application of traditional Chinese medicine composition in preparation of medicine for treating or improving gastrointestinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112870309A true CN112870309A (en) | 2021-06-01 |
Family
ID=76040653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110412331.6A Pending CN112870309A (en) | 2021-04-16 | 2021-04-16 | Application of traditional Chinese medicine composition in preparation of medicine for treating or improving gastrointestinal diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112870309A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116098972A (en) * | 2022-12-09 | 2023-05-12 | 葵花药业集团（贵州）宏奇有限公司 | A Chinese medicinal composition for regulating expression level of RhoA/ROCK pathway related protein in antrum of stomach, and its application in preparing medicine |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1343508A (en) * | 2001-01-09 | 2002-04-10 | 刘宝泉 | Chinese patent medicine for treating peptic ulcer |
| CN103505690A (en) * | 2013-10-17 | 2014-01-15 | 李云启 | Medicament for treating chronic gastrointestinal tract diseases and preparation method of medicament |
| CN105362906A (en) * | 2015-11-29 | 2016-03-02 | 王宁 | Traditional Chinese medicine for treating spleen-stomach deficiency and food stagnation symptoms of children and method for preparing traditional Chinese medicine |
| CN106474413A (en) * | 2016-11-09 | 2017-03-08 | 扬子江药业集团上海海尼药业有限公司 | A kind of Orally administered composition for treating child's weakness of the spleen and stomach, eating accumulation, anorexia |
| CN106620485A (en) * | 2016-11-09 | 2017-05-10 | 扬子江药业集团上海海尼药业有限公司 | Preparation method of oral digestion-promoting medicated leaven composition |
-
2021
- 2021-04-16 CN CN202110412331.6A patent/CN112870309A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1343508A (en) * | 2001-01-09 | 2002-04-10 | 刘宝泉 | Chinese patent medicine for treating peptic ulcer |
| CN103505690A (en) * | 2013-10-17 | 2014-01-15 | 李云启 | Medicament for treating chronic gastrointestinal tract diseases and preparation method of medicament |
| CN105362906A (en) * | 2015-11-29 | 2016-03-02 | 王宁 | Traditional Chinese medicine for treating spleen-stomach deficiency and food stagnation symptoms of children and method for preparing traditional Chinese medicine |
| CN106474413A (en) * | 2016-11-09 | 2017-03-08 | 扬子江药业集团上海海尼药业有限公司 | A kind of Orally administered composition for treating child's weakness of the spleen and stomach, eating accumulation, anorexia |
| CN106620485A (en) * | 2016-11-09 | 2017-05-10 | 扬子江药业集团上海海尼药业有限公司 | Preparation method of oral digestion-promoting medicated leaven composition |
Non-Patent Citations (6)
| Title |
|---|
| 周德生: "《实用临床中西药合用解读》", 31 December 2016, 山西科学技术出版社 * |
| 李冉: "神曲消食口服液联合推拿疗法治疗小儿厌食脾失健运证的临床疗效", 《西南医科大学学报》 * |
| 沈丕安: "《中药药理与临床运用》", 30 June 2020, 吉林科学技术出版社 * |
| 蔡永敏: "《最新中药药理与临床应用》", 31 January 1999, 华夏出版社 * |
| 金秉俊: "慢性胃炎中医证候学研究", 《中国优秀博硕士学位论文全文数据库（硕士） 医药卫生科技辑》 * |
| 陈长勋: "《中药药理学》", 31 January 2015, 上海科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116098972A (en) * | 2022-12-09 | 2023-05-12 | 葵花药业集团（贵州）宏奇有限公司 | A Chinese medicinal composition for regulating expression level of RhoA/ROCK pathway related protein in antrum of stomach, and its application in preparing medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112006137A (en) | Spleen-tonifying and stomach-nourishing Su-radish tea and preparation method thereof | |
| WO2016163652A1 (en) | Health supplement food for promotion of hair growth, mitigation and alleviation of hair loss, regulation of blood glucose, and alleviation and relief of gastric disorder symptoms | |
| WO2014201637A1 (en) | Compound preparation for treating cervical spondylosis with radiculopathy and preparation method therefor | |
| CN111388587A (en) | Traditional Chinese medicine composition for preparing medicine for treating functional dyspepsia | |
| CN112870309A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating or improving gastrointestinal diseases | |
| CN114246918A (en) | Traditional Chinese medicine composition for treating hashimoto thyroiditis and preparation method thereof | |
| CN113648386A (en) | Medicinal and edible compound composition and application thereof | |
| CN105832991B (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN110604773B (en) | Composition for regulating lipid metabolism disorder and preparation method and application thereof | |
| CN111529608A (en) | Application of preparation for removing food retention and relieving cough for children in preparation of medicine for treating fever and preparation method thereof | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| WO2013115534A1 (en) | Composition for preventing or treating multiple sclerosis | |
| CN107823293A (en) | Treat Yao nationality medicine external pulvis of canker sore and preparation method thereof | |
| CN112022984A (en) | Preparation for removing food retention, preparation method and application thereof | |
| CN113304135B (en) | Composition for treating diabetic gastroparesis and application thereof | |
| CN112156162B (en) | Medicine for protecting gastric mucosa and preparation method thereof | |
| CN115944699B (en) | Traditional Chinese medicine composition with effects of activating spleen and tonifying qi, and promoting digestion and resolving stagnation, preparation method and application thereof | |
| CN113018351B (en) | Pharmaceutical composition, pharmaceutical preparation, and preparation method and application thereof | |
| CN108576821A (en) | A kind of compound formulation of regulation and control fat metabolism gene expression and preparation method and application | |
| WO2004084924A1 (en) | Pharmaceutical composition for treatment of bph and preparation thereof | |
| CN115779039B (en) | Pharmaceutical composition for treating postmenopausal osteoporosis | |
| CN114246903B (en) | Application of Xintong preparation in preparing medicament for treating chronic bronchitis and preparation method thereof | |
| CN114848781B (en) | A Chinese medicinal composition for treating bradyarrhythmia and preparation method thereof | |
| CN107519429B (en) | Have the function of to improve taste and promote the Chinese medicine composition and preparation method of catharsis and toxin expelling | |
| CN117462644A (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |